Pfizer’s etrasimod hits goals again in ulcerative colitis study
March 29, 2022 at 07:25 AM EDT
Pfizer Inc. on Tuesday said a second Phase 3 study of its recently acquired investigational drug etrasimod met the main endpoints in the treatment of moderately to severely active ulcerative colitis, a chronic inflammatory bowel disease.